公开(公告)号：US11517577B2

公开(公告)日：2022-12-06

申请号：US17262915

申请日：2019-07-30

Applicant: NZP UK LIMITED ,  THE UNIVERSITY OF SOUTHAMPTON

Inventor： Alexander Charles Weymouth-Wilson ,  Gemma Packer ,  Bruno Jan Pol Linclau ,  Dannielle Kydd-Sinclair ,  Kimberly Ann Watson

IPC: A61K31/64 ,  A61P1/16 ,  A61K31/575 ,  C07J41/00

Abstract: The invention relates to compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; and liver damage arising from fibrosis.

公开(公告)号：US20220073557A1

公开(公告)日：2022-03-10

申请号：US17415216

申请日：2019-12-20

Applicant: NZP UK LIMITED ,  THE UNIVERSITY OF SOUTHAMPTON

Inventor： Alexander Charles Weymouth-Wilson ,  Bruno Jan Pol Linclau ,  Gemma Packer ,  Joseph Watts ,  Heather Mortiboys ,  Oliver Bandmann ,  Christopher Hastings

IPC: C07J9/00 ,  A61P25/28 ,  A61P25/16 ,  C07J31/00 ,  C07J43/00 ,  C07J33/00

Abstract: Compounds of general formula (1): wherein R1, R2 and R3 are as defined herein; are of use in the treatment and prevention of neurodegenerative disorders including Alzheimer's disease and Parkinson's disease.

公开(公告)号：US20210299148A1

公开(公告)日：2021-09-30

申请号：US17262915

申请日：2019-07-30

Applicant: NZP UK LIMITED ,  THE UNIVERSITY OF SOUTHAMPTON

Inventor： Alexander Charles Weymouth-Wilson ,  Gemma Packer ,  Bruno Jan Pol Linclau ,  Dannielle Kydd-Sinclair ,  Kimberly Ann Watson

IPC: A61K31/64 ,  A61P1/16 ,  C07J41/00 ,  A61K31/575

Abstract: The invention relates to compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; and liver damage arising from fibrosis.

公开(公告)号：US20150037790A1

公开(公告)日：2015-02-05

申请号：US14325067

申请日：2014-07-07

Applicant: The University of Southampton

Inventor： Keith R. Fox ,  Tom Brown ,  Scott T. Kimber

IPC: C12Q1/68

CPC classification number: C12Q1/683 ,  C12Q2521/531 ,  C12Q2537/164

Abstract: This invention relates to methods for variant cytosine detection, and kits and probes for variant cytosine detection. In particular the variant cytosine detection is related to detection of methylated cytosine, hydroxymethylated cytosine, carboxycytosine and/or formylcytosine in nucleic acid.

Abstract translation: 本发明涉及用于变体胞嘧啶检测的方法，以及用于变体胞嘧啶检测的试剂盒和探针。 特别地，变体胞嘧啶检测与核酸中甲基化胞嘧啶，羟甲基化胞嘧啶，羧基胞嘧啶和/或甲酰胞嘧啶的检测有关。

公开(公告)号：US20030118315A1

公开(公告)日：2003-06-26

申请号：US10210074

申请日：2002-08-02

Applicant: THE UNIVERSITY OF SOUTHAMPTON

Inventor： Daniel William Hewak ,  Mohammed Khawar Arshad Mairaj

IPC: G02B006/16 ,  G02B006/10 ,  G02B006/20 ,  C04B035/547 ,  C04B035/50

CPC classification number: C03B37/027 ,  C03B37/023 ,  C03B2201/88 ,  C03C3/23 ,  C03C3/323 ,  C03C13/044 ,  C03C13/048

Abstract: A new and improved hybrid of Ga:La:S (GLS) glass is provided, namely a glass comprising gallium sulfide, lanthanum oxide, and at least 2 mol % lanthanum fluoride. The Ga:La:S:O:F (GLSOF) glass retains the important properties of the Ga:La:S system, while introducing improved thermal stability and spectroscopic properties. In addition, GLSOF glasses are non-toxic. The glass formation region for GLSOF has been carefully evaluated with compositional variations. It has been identified that an area of glass formation as indicated by circles, is a new and previously undiscovered glass formation region.

Abstract translation: 提供了一种新的改进的Ga：La：S（GLS）玻璃的混合物，即包含硫化镓，氧化镧和至少2mol％氟化镧的玻璃。 Ga：La：S：O：F（GLSOF）玻璃保留了Ga：La：S系统的重要性质，同时引入了改进的热稳定性和光谱性质。 另外，GLSOF眼镜是无毒的。 GLSOF的玻璃形成区域已经通过组成变化进行了仔细的评估。 已经确定，由圆形表示的玻璃形成区域是新的和先前未发现的玻璃形成区域。

公开(公告)号：US20230140713A1

公开(公告)日：2023-05-04

申请号：US17905873

申请日：2021-03-19

Applicant: SECRETARY OF STATE FOR HEALTH AND SOCIAL CARE ,  THE UNIVERSITY OF SOUTHAMPTON

Inventor： John Mark Sutton ,  Charlotte Hind ,  Hywel Morgan ,  Daniel Spencer

IPC: C12Q1/18 ,  G01N15/02 ,  G01N15/10

Abstract: Methods are presented which use impedance flow cytometry for rapid susceptibility testing of antimicrobial agents including phage, antimicrobial peptides and rapid analysis of antimicrobial mediated serum bactericidal assays.